On November 13, 2025, Teva Pharmaceutical Industries Ltd. released its financial and operational results for the third quarter of 2025, highlighting the challenges and strategic developments in its Europe segment. While the company continues to advance its innovative product pipeline and reinforce global operations, its European pharmaceutical business encountered headwinds. The quarterly report provides a detailed examination of core B2B pharmaceuticals dynamics, focusing on manufacturing, R&D investment, portfolio expansion, and supply chain trends across Europe.

The European segment, comprising the European Union, United Kingdom, and additional European countries, reported revenues of $1,235 million for Q3 2025. This figure represents a 2% decrease compared to the same period in 2024, or a 10% decrease when adjusted for local currency fluctuations. The decline primarily stemmed from reduced proceeds from product rights sales in 2024 and lower revenues from generic medicines, partially offset by increased sales from new product introductions.

Teva’s generic products—including OTC and biosimilar portfolio—generated $982 million in revenue for the quarter within the European region, reflecting a modest 1% growth against Q3 2024. However, local currency figures point to a 5% decline due to persistent pricing pressures, shifting market dynamics, and volume fluctuations, balanced slightly by the uptake of recently launched generics. Particularly noteworthy was the continued robust performance of AJOVY, Teva’s innovative biologic for migraine prevention, which saw European sales climb 18% year-on-year to $66 million, driven by increased adoption and expanded market coverage.

Other products showed contrasting trends. COPAXONE, Teva’s legacy multiple sclerosis therapy, reported a sharp 18% revenue drop to $44 million due to ongoing price competition and availability of alternatives. Respiratory product revenue also dipped by 13% to $52 million, impacted by net price reductions and reduced volumes as therapy preferences evolved and generics gained share.

The segment’s gross profit was $665 million (down 5%), and profit margin narrowed to 53.9% versus 55.2% last year. Higher selling and marketing expenditures, as well as less favorable product sales mix, contributed to a segment profit of $303 million, a notable 19% decrease from the prior year. Despite these pressures, Teva sustained its research and development momentum. Q3 2025 saw R&D expenses rise to $256 million, up 7% year-on-year, largely due to investment in expanding its immunology projects and building early-stage innovative capabilities in areas such as neuropsychiatry—offset somewhat by strategic partnership reimbursements received in the previous year.

Teva’s management, led by President and CEO Richard Francis, remain optimistic about the company’s long-term prospects. Although regional revenue challenges persist, Teva’s transformative "Pivot to Growth" strategy centers on fortifying its innovative medicines platform while leveraging its established generics base. Strategic hedging activities have softening gross margin headwinds, and Teva’s commitment to product launches, digital transformation, and operational excellence are expected to position the Europe segment for sustained success amid a competitive marketplace.

On the regulatory and compliance front, Teva is closely monitoring macroeconomic and market shifts affecting pharmaceutical supply chains and pricing in Europe. The company also remains engaged with global partners to optimize its product portfolio, adapt manufacturing operations, and align with evolving European regulatory standards. Overall, Teva’s Q3 2025 results underscore the importance of innovation-driven growth, rigorous supply chain management, and the ongoing realignment of product portfolios in the dynamic European pharma landscape.